A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Top Cited Papers
- 4 March 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 115 (9), 1703-1708
- https://doi.org/10.1182/blood-2009-09-245837
Abstract
Age older than 65 years, hemoglobin level lower than 100 g/L (10 g/dL), white blood cell count greater than 25 × 109/L, peripheral blood blasts 1% or higher, and constitutional symptoms have been shown to predict poor survival in primary myelofibrosis (PMF) at diagnosis. To investigate whether the acquisition of these factors during follow-up predicts survival, we studied 525 PMF patients regularly followed. All 5 variables had a significant impact on survival when analyzed as time-dependent covariates in a multivariate Cox proportional hazard model and were included in 2 separate models, 1 for all patients (Dynamic International Prognostic Scoring System [DIPSS]) and 1 for patients younger than 65 years (age-adjusted DIPSS). Risk factors were assigned score values based on hazard ratios (HRs). Risk categories were low, intermediate-1, intermediate-2, and high in both models. Survival was estimated by the HR. When shifting to the next risk category, the HR was 4.13 for low risk, 4.61 for intermediate-1, and 2.54 for intermediate-2 according to DIPSS; 3.97 for low risk, 2.84 for intermediate-1, and 1.81 for intermediate-2 according to the age-adjusted DIPSS. The novelty of these models is the prognostic assessment of patients with PMF anytime during their clinical course, which may be useful for treatment decision-making.Keywords
This publication has 30 references indexed in Scilit:
- Dynamic Model for Predicting Death Within 12 Months in Patients With Primary or Post–Polycythemia Vera/Essential Thrombocythemia MyelofibrosisJournal of Clinical Oncology, 2009
- The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease courseBlood, 2009
- Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis—increased serum ferritin or transfusion load does notAmerican Journal of Hematology, 2009
- Karyotype complements the International Prognostic Scoring System for primary myelofibrosisEuropean Journal of Haematology, 2009
- Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survivalLeukemia, 2008
- Choosing between stem cell therapy and drugs in myelofibrosisLeukemia, 2008
- Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasiaCancer, 2005
- A Gain-of-Function Mutation ofJAK2in Myeloproliferative DisordersNew England Journal of Medicine, 2005
- Identification of ‘short‐lived’ and ‘long‐lived’ patients at presentation of idiopathic myelofibrosisBritish Journal of Haematology, 1997
- Primary myelofibrosis: A detailed statistical analysis of the clinicopathological variables influencing survivalAnnals of Hematology, 1994